February 26, 2020 / 9:58 PM / a month ago

BRIEF-Viking Therapeutics Reports Q4 And Year-End 2019 Financial Results

Feb 26 (Reuters) - Viking Therapeutics Inc:

* VIKING THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

* Q4 LOSS PER SHARE $0.10

* Q4 EARNINGS PER SHARE ESTIMATE $-0.13 — REFINITIV IBES DATA

* PHASE 2B VOYAGE STUDY OF VK2809 IN BIOPSY-CONFIRMED NASH UNDERWAY

* ADDITIONAL VK2809 PHASE 2 RESULTS SELECTED FOR PODIUM PRESENTATION AT EASL

* IND FILING FOR VK0214 IN X-ALD EXPECTED IN 2Q20

* AT DECEMBER 31, 2019, VIKING HELD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALING $275.6 MILLION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below